Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001209191-23-011704 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-22 | 2023-02-21 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $293.75 | -480 | 60.8K | -0.8% | -$141.0K |
| 2023-02-22 | 2023-02-17 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $292.85 | -4,498 | 60.9K | -7% | -$1.32M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-21 | S | D | 124 | $294.77 | 60,467 | D | — | — | (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37). |
| 2 | Common | Common Stock | 2023-02-21 | S | D | 207 | $293.83 | 60,591 | D | — | — | (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38). |
| 3 | Common | Common Stock | 2023-02-21 | S | D | 4 | $291.01 | 60,943 | D | — | — | |
| 4 | Common | Common Stock | 2023-02-17 | F | D | 4,498 | $292.85 | 60,947 | D | — | — | |
| 5 | Common | Common Stock | 2023-02-21 | S | D | 145 | $292.85 | 60,798 | D | — | — | (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36). |